Bulk Pharmaceutical API Sources for pimecrolimus

Bulk Pharmaceutical API Sources for pimecrolimus

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-749
AKos Consulting & Solutions		AKOS015895946
Finetech Industry Limited		FT-0658870
AbaChemScene		CS-2691
MedChemexpress MCE		HY-13723
AvaChem Scientific		137071-32-0
AvaChem Scientific		2188

Pimecrolimus Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

What is the Global Supply of Pimecrolimus API?

The global supply of pimecrolimus bulk active pharmaceutical ingredient (API) is characterized by a concentrated manufacturing base, primarily located in India and China. These regions dominate production due to established chemical synthesis capabilities, cost advantages, and regulatory familiarity. Key players focus on adhering to stringent Good Manufacturing Practice (GMP) standards to meet the requirements of regulated markets in North America and Europe. Demand for pimecrolimus API is directly linked to the production of topical formulations, primarily Elidel, used for treating atopic dermatitis.

Who are the Primary Manufacturers of Pimecrolimus API?

Primary manufacturers of pimecrolimus API are predominantly based in India and China. These companies specialize in complex organic synthesis and have invested in facilities compliant with international regulatory standards.

• Indian Manufacturers:

  • Divi's Laboratories: A significant producer of APIs, including immunosuppressants, with a strong track record in regulatory filings.
  • Laurus Labs: Engaged in the development and manufacturing of APIs across various therapeutic segments.
  • Aurobindo Pharma: While known for finished dosage forms, Aurobindo also has API manufacturing capabilities.
  • Granules India: A major API manufacturer with a broad product portfolio.

• Chinese Manufacturers:

  • Hengrui Medicine: A leading Chinese pharmaceutical company with significant API production capacity.
  • WuXi AppTec: A contract research, development, and manufacturing organization (CRDMO) that provides API services.
  • Zhejiang NHU Company: A key player in the fine chemical and pharmaceutical ingredient sectors.

These manufacturers typically operate multi-purpose facilities capable of producing a range of complex APIs. Their ability to scale production, manage supply chains, and maintain quality control is critical for meeting global demand.

What are the Key Regulatory Considerations for Pimecrolimus API?

The regulatory landscape for pimecrolimus API is rigorous, focusing on ensuring product quality, safety, and efficacy. Manufacturers must comply with guidelines set by major regulatory bodies.

• Good Manufacturing Practice (GMP): Compliance with ICH Q7 guidelines is mandatory. This involves detailed documentation, process validation, quality control testing, and stringent facility standards. Inspections by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are common for API suppliers targeting these markets.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. Marketing authorization holders (MAHs) for finished drug products reference these DMFs in their applications.
• Impurity Profiling: Strict control over process-related impurities, residual solvents, and potential genotoxic impurities is essential. Analytical methods must be validated to detect and quantify impurities at trace levels.
• Pharmacopeial Standards: API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).
• Site Audits: Finished dosage form manufacturers conduct regular audits of their API suppliers to ensure ongoing compliance with quality agreements and regulatory requirements.

What are the Production Processes and Chemical Synthesis Routes for Pimecrolimus API?

Pimecrolimus (also known as ascomycin or SDZ-333-02) is a macrocyclic lactam derived from ascomycin. Its synthesis involves complex multi-step organic chemistry, often starting from fermentation products or advanced intermediates.

The synthesis generally involves:

1. Ascomycin Derivatization: Pimecrolimus is a derivative of ascomycin, an immunosuppressant produced by fermentation of Streptomyces hygroscopicus var. ascomyceticus. The key modification involves selective functionalization of the ascomycin molecule.
2. Selective Functionalization: The process focuses on modifying the hydroxyl group at the C32 position of ascomycin to introduce the characteristic chlorobenzyl ether moiety. This often requires regioselective protection and deprotection strategies to ensure the reaction occurs at the desired site.
3. Key Reactions:
   • Protection of reactive groups: Hydroxyl groups and amine functionalities may require temporary protection to prevent unwanted side reactions.
   • Alkylation: The introduction of the 4-chloro-3-methoxybenzyl group is typically achieved through an alkylation reaction.
   • Deprotection: Removal of protecting groups to yield the final pimecrolimus molecule.
4. Purification: The crude product undergoes rigorous purification steps, often involving chromatography (e.g., High-Performance Liquid Chromatography - HPLC) and crystallization, to achieve the required purity profile.
5. Quality Control: Comprehensive analytical testing, including HPLC for assay and purity, mass spectrometry for structural confirmation, and Karl Fischer titration for water content, is performed.

The complexity of the synthesis necessitates specialized chemical expertise and advanced manufacturing infrastructure. Optimization of yields and reduction of impurities are critical for economic viability.

What are the Market Dynamics and Demand Drivers for Pimecrolimus API?

The market for pimecrolimus API is primarily driven by the prevalence of atopic dermatitis and the established efficacy of topical pimecrolimus formulations.

• Prevalence of Atopic Dermatitis: Atopic dermatitis is a chronic inflammatory skin disease affecting a significant global population, particularly children and adults. The increasing incidence and awareness of this condition directly translate to higher demand for effective treatment options.
• Productivity of Elidel: Elidel (pimecrolimus cream 1%) is a well-established topical calcineurin inhibitor. It offers an alternative to topical corticosteroids, particularly for sensitive skin areas or long-term management, thereby sustaining its market share.
• Generic Competition: The expiry of patents for branded Elidel has led to the entry of generic pimecrolimus creams. This expansion of generic offerings increases the overall volume demand for pimecrolimus API as more manufacturers enter the market.
• Geographic Market Expansion: Increased healthcare access and prescription rates in emerging markets contribute to growing demand for pimecrolimus API.
• Therapeutic Alternatives: While pimecrolimus is a key treatment, the development of new therapies, including biologics, can influence market dynamics. However, topical treatments remain a first-line or second-line option for many patients.
• API Sourcing Strategies: Pharmaceutical companies manufacturing generic pimecrolimus creams actively seek reliable and cost-effective API suppliers, often engaging in long-term supply agreements.

The market size is moderate, influenced by the volume required for topical formulations rather than systemic administration. Pricing is competitive, reflecting the generic nature of many finished products.

What are the Key Supply Chain Considerations and Potential Risks?

The supply chain for pimecrolimus API involves several critical considerations and potential risks that necessitate careful management by pharmaceutical companies.

• Geographic Concentration: The reliance on a limited number of manufacturers in India and China creates a concentration risk. Geopolitical instability, trade disputes, or localized regulatory issues in these regions can disrupt supply.
• Raw Material Sourcing: The synthesis of pimecrolimus relies on specific chemical precursors and intermediates. Disruptions in the availability or quality of these upstream materials can impact API production.
• Quality Control and Assurance: Ensuring consistent API quality from multiple suppliers requires robust quality agreements, regular audits, and stringent incoming material testing. Batch-to-batch variability can affect the performance of the finished drug product.
• Regulatory Compliance: Changes in GMP requirements or the emergence of new impurity concerns can necessitate process modifications, potentially leading to supply delays or increased costs.
• Lead Times and Inventory Management: The multi-step synthesis and purification processes for pimecrolimus API result in significant lead times. Effective inventory management is crucial to avoid stockouts while minimizing carrying costs.
• Intellectual Property: While the primary patents for Elidel have expired, manufacturing processes and specific intermediate syntheses might still be subject to intellectual property considerations, requiring due diligence.
• Logistics and Transportation: Global shipping and customs clearance can introduce delays. Ensuring secure and compliant transportation of APIs is vital.
• Single-Source Dependence: Over-reliance on a single API supplier, even with strong contractual terms, exposes companies to significant risk in case of manufacturing issues or supplier insolvency. Dual or multi-sourcing strategies are often employed to mitigate this.

What are the Future Trends in Pimecrolimus API Sourcing?

Future trends in pimecrolimus API sourcing are likely to be shaped by ongoing market dynamics, regulatory evolution, and technological advancements.

• Diversification of Manufacturing: While India and China will likely remain dominant, there may be efforts to establish or strengthen API manufacturing capabilities in other regions to enhance supply chain resilience and reduce geopolitical risks.
• Increased Focus on Sustainability: Growing emphasis on environmental, social, and governance (ESG) factors will likely lead to greater scrutiny of manufacturing processes, waste management, and energy consumption by API suppliers. Companies may favor partners with demonstrable sustainability initiatives.
• Advanced Analytical Technologies: The implementation of Process Analytical Technology (PAT) and other real-time monitoring tools could improve process control, reduce batch failures, and enhance overall quality assurance in API manufacturing.
• Vertical Integration by Finished Product Manufacturers: Some larger pharmaceutical companies may consider increased vertical integration, bringing API manufacturing in-house or establishing closer strategic partnerships to secure supply and control quality more effectively.
• Continuous Manufacturing: The pharmaceutical industry is exploring continuous manufacturing for APIs. If adopted for pimecrolimus, this could lead to more efficient, agile, and potentially cost-effective production with smaller facility footprints.
• Enhanced Supply Chain Transparency: Greater demand for end-to-end supply chain visibility will drive the adoption of digital tools and blockchain technologies for tracking materials from raw ingredients to finished APIs.

Key Takeaways

• Pimecrolimus API manufacturing is concentrated in India and China, serving global demand for topical dermatological treatments.
• Key regulatory hurdles include strict GMP compliance, robust impurity control, and successful DMF filings with authorities like the FDA and EMA.
• The synthesis is a complex multi-step process involving the derivatization of ascomycin, requiring specialized chemical expertise.
• Market demand is sustained by the prevalence of atopic dermatitis and the established role of pimecrolimus creams, amplified by generic product entries.
• Supply chain risks include geographic concentration, raw material volatility, and stringent quality assurance requirements.
• Future trends point towards supply chain diversification, sustainability initiatives, and the adoption of advanced manufacturing technologies.

Frequently Asked Questions

What is the typical lead time for pimecrolimus API orders?

Lead times for pimecrolimus API orders can range from 3 to 6 months, depending on the supplier's production schedule, current inventory levels, and the quantity ordered. This is influenced by the multi-step synthesis and purification processes involved.

How can pharmaceutical companies ensure the quality of pimecrolimus API from overseas suppliers?

Companies can ensure API quality through rigorous supplier qualification processes, including site audits, review of regulatory filings (DMFs), detailed quality agreements, and comprehensive testing of incoming API batches for identity, purity, and potency against pharmacopeial standards.

Are there any significant environmental concerns associated with pimecrolimus API manufacturing?

Complex organic synthesis often involves the use of solvents and reagents, which can generate waste streams. Responsible API manufacturers implement waste minimization strategies, solvent recovery processes, and wastewater treatment to comply with environmental regulations and mitigate impact.

What is the pricing trend for pimecrolimus API in the current market?

Pricing for pimecrolimus API is competitive, particularly with the increased availability of generic finished products. Prices are subject to raw material costs, manufacturing efficiencies, regulatory compliance expenses, and the volume of orders. Fluctuations can occur based on global supply-demand dynamics.

Beyond topical dermatitis, are there other therapeutic applications for pimecrolimus API that impact demand?

While pimecrolimus is primarily known for treating atopic dermatitis topically, it is an analog of tacrolimus, a calcineurin inhibitor used systemically as an immunosuppressant. However, the bulk API demand for pimecrolimus is overwhelmingly driven by its dermatological application; systemic use of related compounds like tacrolimus does not significantly influence pimecrolimus API demand.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files-dmfs [2] European Medicines Agency. (n.d.). Active substances (Active Pharmaceutical Ingredients). Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapies/active-substances-active-pharmaceutical-ingredients [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Single/Q7_Guideline.pdf [4] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.uspnf.com/pharmacopeial-forum [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia